Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Research & Development (2020 - 2024)

Immuneering (IMRX) has 5 years of Research & Development data on record, last reported at $14.9 million in Q4 2024.

  • For Q4 2024, Research & Development rose 24.74% year-over-year to $14.9 million; the TTM value through Dec 2024 reached $48.0 million, up 15.23%, while the annual FY2024 figure was $48.0 million, 15.23% up from the prior year.
  • Research & Development reached $14.9 million in Q4 2024 per IMRX's latest filing, up from $11.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.9 million in Q4 2024 and bottomed at $4.1 million in Q3 2020.
  • Average Research & Development over 5 years is $9.0 million, with a median of $9.4 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 68.03% in 2022, then rose 7.33% in 2023.
  • A 5-year view of Research & Development shows it stood at $4.9 million in 2020, then surged by 62.57% to $8.0 million in 2021, then rose by 24.17% to $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023, then grew by 24.74% to $14.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Research & Development were $14.9 million in Q4 2024, $11.3 million in Q3 2024, and $10.7 million in Q2 2024.